SCHEDULE 13D/A: Saba Capital Management Amends Stake in BlackRock Science & Technology Term Trust, Discloses Recent Share Sales

Saba Capital Management, L.P. and its affiliates have filed an Amendment No. 8 to their Schedule 13D, disclosing a 5.77% beneficial ownership in BlackRock Science & Technology Term Trust and detailing recent open market transactions, primarily sales.

Summary

• Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (the "Reporting Persons") collectively beneficially own 4,066,572 common shares of BlackRock Science & Technology Term Trust.
• This represents 5.77% of the issuer's common stock outstanding, calculated based on 70,506,820 shares as of May 19, 2025, as disclosed in the company's DEF 14A.
• The total amount paid to acquire the reported common shares is approximately $69,909,579.
• Funds for the share purchases were derived from investor subscription proceeds, capital appreciation, and margin account borrowings.
• The filing details numerous open market transactions within the past sixty days prior to May 22, 2025, predominantly sales, with some purchases.
• Notable transactions include a sale of 655,201 shares at $20.00 on May 22, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the predominant selling activity by a significant shareholder, which could be interpreted as a lack of conviction or profit-taking, potentially signaling a less favorable outlook for the stock from their perspective. However, the filing itself is a routine disclosure and doesn't contain negative news about the issuer's operations.

Positives

• The Reporting Persons have not been involved in criminal proceedings or civil proceedings related to federal or state securities laws in the last five years.
• The investment has seen capital appreciation, contributing to the source of funds for share acquisitions.

Negatives

• The recent transactions primarily consist of sales, indicating a reduction in exposure or profit-taking by the Reporting Persons, which could be perceived negatively by the market.

Risks

• The use of margin account borrowings for share purchases introduces leverage risk, as positions held in margin accounts are pledged as collateral security for repayment of debit balances.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the issuer's future performance or the Reporting Persons' future investment intentions beyond the disclosure of current ownership and past transactions.

Industry Context

This filing reflects an institutional investor's (Saba Capital Management) active management of its position in a closed-end fund, BlackRock Science & Technology Term Trust. Such filings are common for activist investors or large shareholders adjusting their holdings, often signaling a change in their investment thesis or a move to realize gains. The specific sales activity could indicate a view on the valuation of technology and science sectors or the specific trust.

Legal Proceedings

• The Reporting Persons (Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein) have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws, or finding any violation with respect to such laws, during the last five years.

Stakeholder Impact

• Shareholders: The disclosure of a significant shareholder reducing their stake could influence market perception and potentially the share price, depending on how the market interprets the selling activity (e.g., profit-taking vs. loss of confidence).

Key Dates

Recommendation

Keywords

Saba Capital Management, BlackRock Science & Technology Term Trust, Schedule 13D/A, Beneficial Ownership, Share Sales, Investment Fund, Closed-End Fund, SEC Filing, Institutional Investor, Boaz R. Weinstein